Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway

Abstract

Management of diabetic nephropathy (DN) is far from satisfactory. There is a rising role of the involvement of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway in the pathogenesis of DN. This study aimed at investigating the renoprotective effects of PI3K/AKT pathway via sitagliptin in a rat model of DN. Thirty-two male Wistar rats were divided into four groups (eight rats each): (I) control, (II) sitagliptin, (III) DN, and (IV) DN + sitagliptin. Fasting blood glucose (FBG), kidney index, and kidney function tests in both blood and urine were measured. The levels of superoxide dismutase (SOD), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) and gene expressions of PI3K, pPI3K, AKT, and pAKT in renal tissue were detected. Renal histopathological and immunohistochemical studies were evaluated. DN + sitagliptin group showed significant decrease in FBG and kidney index, improvement in kidney function tests, and a decrease in levels of TNF-α and TGF-β in renal tissues compared with DN group. This was associated with significant increase in SOD and gene expressions of PI3K and AKT and their phosphorylated active forms in renal tissue in DN + sitagliptin group compared with DN group. Moreover, DN + sitagliptin group showed apparent decrease in amount of collagen fibers and expression of alpha-smooth muscle actin (α-SMA) compared with DN group. This work shows that sitagliptin improved renal functions and histopathological changes, impeded inflammation, and oxidative stress and upregulated PI3K/AKT pathway which highlights its renoprotective effects in a rat model of DN.

The Potential Modulating Impact of the Dipeptidyl Peptidase-4 (Dpp-4) Inhibitor, Sitagliptin on Streptozotocin-Nicotinamide-Induced Diabetic Nephropathy in Rats

“…Additionally, 16 weeks of treatment with low-or high-dose sitagliptin dramatically reduced serum urea and creatinine, urine albumin (microalbuminuria) levels in Wistar rats. The same sitagliptin therapy also led to improvements in glomerular lesions 48 .…”

Di-PEGylated insulin: A long-acting insulin conjugate with superior safety in reducing hypoglycemic events

“…While in treated groups (insulin or di-PEGylated insulin), these pathological features were somewhat attenuated (such as normal glomeruli and narrow irregular urinary space), particularly di-PEGylated insulin. For PAS staining, thicker glomerular basement membrane and incomplete brush border were noticed in mice treated with PBS or insulin 31 . While in the di-PEGylated insulin group, most renal tubules were presented with completed brush border and glomerulus were seen with preserved glomerular basement membrane.…”

“…As a negative control, representative H&E images of PBS-treated mice showed classical diabetic pathology, e.g. , shrunken glomeruli, wide irregular urinary space, and vacuolated renal tubular cells 31 . While in treated groups (insulin or di-PEGylated insulin), these pathological features were somewhat attenuated (such as normal glomeruli and narrow irregular urinary space), particularly di-PEGylated insulin.…”

Frequency of Mortality and Adverse Outcomes of COVID-19 in Hospitalized Type 2 Diabetics with a History of Sitagliptin or Metformin Use

“…Sitagliptin not only lowers blood glucose levels but also exhibits anti-inflammatory (14,15) and immunomodulatory effects (26). Considering the elevated levels of inflammatory factors in COVID-19 (27,28), sitagliptin could help mitigate complications and the disease's severity. It activates AMPK through liver (32).…”